The Filing Desk

Invivyd vs Protalix BioTherapeutics

Invivyd IVVD · Protalix BioTherapeutics PLX · Biotechnology

Invivyd reported revenue of $53 million in fiscal 2025, about the same as Protalix BioTherapeutics' $53 million in fiscal 2025. Invivyd's revenue grew 110.5% in its latest year, and Protalix BioTherapeutics' fell 1.2%. Invivyd had an operating margin of -104.0%, against -10.4% at Protalix BioTherapeutics. Free cash flow was −$58 million at Invivyd and −$14 million at Protalix BioTherapeutics.

Side by side

InvivydProtalix BioTherapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$53M$53M
Revenue growth110.5%−1.2%
Revenue growth a year, last 5 years—−3.5%
Gross margin—48.8%
Operating margin−104.0%−10.4%
Net margin−98.2%−12.5%
Free cash flow−$58M−$14M
Free cash flow margin−109.1%−25.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count45.3%−3.1%
Last close$0.45$3.06
P/E at the last close—12.2×
Insider trades, last 12 monthssold $341,120bought $101,360, sold $0
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
InvivydProtalix BioTherapeutics
Operating margin
Percent of revenue
InvivydProtalix BioTherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InvivydProtalix BioTherapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Invivyd and Protalix BioTherapeutics pages.